- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04768777
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis (BIPAMS-SD)
December 21, 2023 updated by: Donald Lein, University of Alabama at Birmingham
The prevalence of sexual dysfunction is higher among women with multiple sclerosis (MS) than women in the general population.
The presence of sexual dysfunction is associated with decreased well-being and quality of life.
There is limited research supporting pharmacological and other therapeutic approaches for managing sexual dysfunction in MS.
Physical activity has beneficial effects on many of the consequences of MS, and physical activity represents a promising non-pharmacological approach for managing symptoms of sexual dysfunction in MS.
The proposed research examines the effect of an Internet-delivered lifestyle physical activity intervention for improving sexual dysfunction in women with MS.
The research proposed, if successful, will provide evidence for the efficacy of physical activity as a translatable approach for managing sexual dysfunction among women with MS.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Donald Lein, PhD
- Phone Number: 2059340241
- Email: dlein@uab.edu
Study Contact Backup
- Name: Ashlie Ithurburn
- Phone Number: 2059751306
- Email: akji@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35243
- University of Alabama at Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female
- Diagnosed of relapsing remmiting multiple sclerosis
- Relapse free in the past 30 days
- Initial confirmation of sexual dysfunction (based on a semi-structured interview on sexual dysfunction diagnostic criteria in DSM-5)
- Currently in a committed relationship with a partner who does not have a sexual disorder or sexual dysfunction
- Internet and email access
- Willingness to complete the questionnaires, wear the pedometer, and undergo randomization
- Insufficient physical activity [not meeting current physical activity guidelines based on a health contribution score of less than 14 units from the Godin Leisure-Time Exercise Questionnaire (GLTEQ)]
- Ability to ambulate without assistance [self-report and Patient-Determined Disease Steps (PDDS) score between 0 and 2 (mild ambulatory disability)]
- Age between 18 and 45 years
English as primary language
-
Exclusion Criteria:
1. Moderate or high risk for contraindications of possible injury or death when undertaking strenous or maximal exercise
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Behavioral Intervention for Physical Activity in MS (BIPAMS)
A behavioral intervention that involves an internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
|
The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach.
The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory.
Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored.
The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries.
The chats are conducted face-to-face through an online videoconferencing platform.
There are a total of 12 chats over 16 weeks.
Chats occur on weeks 1-8, 10-11, 13 and16.
|
No Intervention: waitlist control condition
Participants will have 16-weeks of no intervention or interaction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Sexual Dysfunction at 16 weeks
Time Frame: Baseline, week 16
|
The Female Sexual Function Index (FSFI): is a common generic measure of sexual dysfunction for women.
The questionnaire consists of 19 questions that cover six subscales/domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, sexual satisfaction, and pain.
The items further yield an overall score.
Lower sum scores reflect more pronounced sexual dysfunction.
|
Baseline, week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Sexual Dysfunction in MS at 16 weeks
Time Frame: Baseline, week 16
|
The Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) is the most widely used self-rating tool for sexual functions in MS (Sanders et al., 2000).
The MSISQ-19 consists of 19 items focusing on the perceived influence of MS symptoms on sexual activity and satisfaction and the perceived influence of MS symptoms on the overall quality of intimate relationships.
The scores classifies the type of sexual dysfunction in to primary, secondary, or tertiary sexual dysfunction.
|
Baseline, week 16
|
Change from baseline Physical activity at 16 weeks
Time Frame: Baseline, week 16
|
GLTEQ: Physical Activity Levels as measured by the Godin Leisure-Time Exercise Questionnaire.
Participants will complete the Godin Leisure-Time Exercise Questionnaire (GLTEQ) as a measure of the frequency of strenuous, moderate, and mild leisure-time physical activity performed for periods of 15 minutes or more over a typical week.
Summary scores are calculated by multiplying the number of strenuous, moderate, and mild bouts by 9, 5, and 3, respectively, and summing those values into an overall score that ranges from 0 to 119; higher scores are represent a greater volume of physical activity.
This will be completed at baseline testing.
|
Baseline, week 16
|
Change from baseline physical activity duration at 16 weeks
Time Frame: Baseline, week 16
|
International Physical Activity Questionnaire (IPAQ).
The IPAQ was developed by a working group initiated by the World Health Organization and the Centers for Disease Control and Prevention.
The IPAQ asks participants about time spent in physical activity over the last seven days.
Minutes of walking, sedentary-, moderate- and vigorous-intensity activities were calculated for the past week.
|
Baseline, week 16
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stability and changes of Fatigue over time
Time Frame: Baseline, week 16
|
Fatigue Severity Scale (FSS); scores range between 1 (min) and 7 (max), higher scores reflect greater fatigue severity.
|
Baseline, week 16
|
Change from Baseline Depression at 16 weeks
Time Frame: Baseline, week 16
|
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.
|
Baseline, week 16
|
Change from Baseline Anxiety at 16 weeks
Time Frame: Baseline, week 16
|
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.
|
Baseline, week 16
|
Change from Baseline Subjective sleep complaints at 16 weeks
Time Frame: Baseline, week 16
|
Insomnia Severity Index (ISI).
This questionnaire is a seven-item screening measure for insomnia.
The items, answered on a 5-point Likert scale ranging from 0 (=not at all) to 4 (=very much), refer in part to the Diagnostic and Statistical Manual of Mental Disorders criteria for insomnia by assessing difficulty falling asleep, difficulty remaining asleep, early morning awakenings, impaired daytime performance, low satisfaction with sleep, and worry about sleep.
The higher the overall score, the more the participant is assumed to suffer from insomnia.
|
Baseline, week 16
|
Change from Baseline Feelings of Loneliness at 16 weeks
Time Frame: Baseline, week 16
|
Short-form UCLA Loneliness Scale is a 3-item scale designed to measure one's subjective feelings of loneliness as well as feelings of social isolation.
|
Baseline, week 16
|
Change from Baseline Pain severity at 16 weeks
Time Frame: Baseline, week 16
|
Short-form of McGill Pain Questionnaire : Change of self-report measures of Pain through the Short-form of McGill Pain.
|
Baseline, week 16
|
Change from Baseline Emotion Regulation at 16 weeks
Time Frame: Baseline, week 16
|
Emotion Regulation Questionnaire(ERQ): A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression.
Respondents answer each item on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree).
Lowersscores reflects better emotion regulation.
|
Baseline, week 16
|
Change from Baseline Couple Satisfaction at 16 weeks
Time Frame: Baseline, week 16
|
Couple Satisfaction Index (CSI-4), is a seven-item questionnaire for assessing the level of couple satisfaction.
The answers are given on a 7-point Likert scale (for question 1) and 6-point Likert scale (for question 2-4) with the following anchor points 0 (= extremely unhappy/not at all satisfied) to 6 or 5 (= Perfect/completely satisfied).
|
Baseline, week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2024
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
February 10, 2021
First Submitted That Met QC Criteria
February 23, 2021
First Posted (Actual)
February 24, 2021
Study Record Updates
Last Update Posted (Actual)
December 22, 2023
Last Update Submitted That Met QC Criteria
December 21, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300006813
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedMultiple SclerosisUnited States
-
University of Alabama at BirminghamCompletedMultiple Sclerosis | Restless Legs SyndromeUnited States
-
University of Illinois at ChicagoEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMultiple SclerosisUnited States
-
University of Alabama at BirminghamCompletedMultiple SclerosisUnited States
-
Hasan Kalyoncu UniversityCompletedMultiple Sclerosis | Muscle Spasticity | Cervical Region Disorder Nos | Pressure AreaTurkey
-
University of SaskatchewanSaskatchewan Centre for Patient-Oriented Research; Saskatchewan Health Research...CompletedMultiple SclerosisCanada
-
Michigan State UniversityCompleted
-
Children's Mercy Hospital Kansas CityCompletedPhysical Activity | Patient EngagementUnited States
-
University Hospital Center of MartiniqueClinique Antilles-GuyaneUnknownDiabetes Mellitus, Type 2France
-
University of MiamiNational Institute of Nursing Research (NINR)Active, not recruitingPhysical Activity | Overweight and Obesity | Adiposity | Nutrient; ExcessUnited States